Friedegund E. Meier

Friedegund E. Meier

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 239 publications

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 11, 2026

Correction: 1H-NMR serum metabolomic profiling from clinical routine identifies signatures of progressive melanoma metastasis.

Correction: 1H-NMR serum metabolomic profiling from clinical routine identifies signatures of progressive melanoma metastasis.

Journal: Scientific reports

Published: July 08, 2026

Cancer survivorship in malignant melanoma.

Cancer survivorship in malignant melanoma.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: March 02, 2026

Living with melanoma: a study protocol for the design and participatory development of a survivorship care programme for people with metastatic melanoma.

Living with melanoma: a study protocol for the design and participatory development of a survivorship care programme for people with metastatic melanoma.

Journal: Skin health and disease

Published: February 17, 2026

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 25, 2026

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 16, 2026

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Journal: Cancers

Published: January 13, 2026

Survivorship care for melanoma patients: a scoping review.

Survivorship care for melanoma patients: a scoping review.

Journal: Journal of cancer survivorship : research and practice

Published: December 29, 2025

Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.

Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.

Journal: Journal for immunotherapy of cancer

Published: December 04, 2025

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Journal: Journal for immunotherapy of cancer

Published: November 30, 2025

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 12, 2025

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 10, 2025

Showing 1-12 of 239

Last Updated: 09/26/2026